ClonaCell™ Media for Hybridoma and CHO Cell Line Development
ClonaCell™ for Hybridoma and Cell Line Development
Liquid and Semi-Solid Media for Efficient Cell Cloning and Generation
Develop , , and other cell types using the ClonaCell™ portfolio of innovative cell line-specific media, designed to provide optimal culture conditions. Available in both methylcellulose-based (semi-solid) and liquid form, ClonaCell™-CHO and ClonaCell™-HY formulations help you achieve a high probability of monoclonality and clonal diversity in just one step.
View all ClonaCell™ media and supplements, and download our brochure to help you choose the right product for your needs.
Use ClonaCell™ to:
- Save time and resources with a proven semi-solid cloning method that overcomes the challenges of traditional limiting dilution cloning
- Nurture and save finicky hybridomas generated from mouse, rat, human, rabbit and hamster cells
- Increase subcloning efficiency during CHO cell line development
Research-stage biotechnology companies and antibodies service companies use ClonaCell™-HY to complete antibody development projects faster and deliver the best antibodies for each application.
Dr. M. Javad Aman, President and CSO, Integrated BioTherapeutics, Inc.
Why Use ClonaCell™?
- Save time with semi-solid cloning. Don’t waste resources on empty cloning wells.
- Superior cloning efficiency and growth of CHO and other cell lines, hybridomas and myelomas.
- Base methylcellulose medium is easily customized for your cell type. Custom formulations, packaging, and additional sizes are available upon request.
- Rigorous performance testing, ensuring lot-to-lot reproducibility.
- Industry-recognized manufacturing expertise and unparalleled technical support.
Try ClonaCell™ in your own lab.
ClonaCell™ for Hybridoma Generation and Expansion
ClonaCell™-HY Hybridoma Kit
Components (Available Separately):
Recommended Applications:
All steps of mouse monoclonal antibody production: cell fusion, semi-solid cloning/selection and expansion of hybridomas
Advantages:
- Combines the hybridoma selection and cloning into one step
- Single-cell derived hybridomas form visible discrete colonies in semi-solid medium for easy picking and screening
- Rare clones not lost through overgrowth
ClonaCell™FLEX
Size:
45 mL
Format:
Semi-solid
Formulation:
- Serum-free
- Chemically defined
- Animal component-free
- Protein-free
- Methylcellulose
- DHFR and GS compatible
Recommended Applications:
- Creating customized semi-solid media for selection and cloning of suspension-adapted CHO cells and hybridomas
- Converting a liquid medium into semi-solid medium for selection and cloning of a wide variety of cell types
- Recloning of established, suspension-adapted CHO cells
Advantages:
- Allows users to create a customized semi-solid medium optimized for a variety of cell types
- Allows users to convert an existing liquid cloning method into a semi-solid cloning method
Resources:
ClonaCell™-HY Liquid HAT Selection Medium
Size:
500 mL
Format:
Liquid
Formulation:
- DMEM
- Pre-selected serum
- L-Glutamine
- Gentamycin
- Supplements
- Hypoxanthine
- Aminopterin
- Thymidine
- 2-Mercaptoethanol
Recommended Applications:
- Selection of hybridomas following cell fusion
- Cloning of individual hybridomas by limiting dilution
Advantages:
Simplifies hybridoma selection in liquid suspension cultures.
Resources:
ClonaCell™-HY Medium D without HAT
Size:
90 mL
Format:
Semi-solid
Formulation:
- DMEM
- Pre-selected serum
- L-Glutamine
- Gentamycin
- Supplements
- Hypoxanthine
- Aminopterin
- Thymidine
- 2-Mercaptoethanol
Recommended Applications:
- One-step selection (if appropriate selective agent is added) and semi-solid cloning of hybridomas
- Used after cell fusion
Advantages:
- Combines the hybridoma selection and cloning into one step
- Single-cell derived hybridomas form visible discrete colonies in semi-solid medium for easy picking, screening, and expanding
- Rare clones not lost through overgrowth
ClonaCell™-HY AOF Expansion Medium
Size:
500 mL
Format:
Liquid
Formulation:
- Hypoxanthine
- Thymidine
- Gentamicin
- L-Glutamine
- Recombinant proteins
Recommended Applications:
- Growth and expansion of hybridomas (mouse, rat) and myelomas (mouse, rat, human)
Advantages:
- Animal origin-free
- Reduces performance variability in the medium
- Simplifies downstream clone screening and antibody purification (no serum-derived IgG)
Resources:
Collapse Details
ClonaCell™-HY Hybridoma Kit Media
ClonaCell™-HY Medium A
Size:
500 mL
Format:
Liquid
Ingredients:
- DMEM
- Pre-selected serum
- L-Glutamine
- Gentamycin
- Supplements
- 2-Mercaptoethanol
Application:
Supports the growth of myeloma cells prior to fusion
ClonaCell™-HY Medium B
Size:
500 mL
Format:
Liquid
Ingredients:
- DMEM
- L-Glutamine
- Gentamycin
- 2-Mercaptoethanol
Application:
Used during the fusion process
ClonaCell™-HY Medium C
Size:
100 mL
Format:
Liquid
Ingredients:
- DMEM
- Pre-selected serum
- L-Glutamine
- Gentamycin
- Supplements
- 2-Mercaptoethanol
Application:
Promotes hybridoma viability after fusion prior to HAT selection
ClonaCell™-HY Medium D
Size:
90 mL
Format:
Semi-solid
Ingredients:
- DMEM
- Pre-selected serum
- L-Glutamine
- Gentamycin
- Supplements
- Hypoxanthine
- Aminopterin
- Thymidine
- 2-Mercaptoethanol
Application:
Used for selection and cloning of hybridomas in one step
ClonaCell™-HY Medium E
Size:
500 mL
Format:
Liquid
Ingredients:
- DMEM
- Pre-selected serum
- L-Glutamine
- Gentamycin
- Supplements
- Hypoxanthine
- Thymidine
- 2-Mercaptoethanol
Application:
Supports hybridoma growth and expansion after HAT selection
Collapse Details
ClonaCell™ for CHO Cell Line Development
ClonaCell™-CHO CD Medium
Size:
90 mL
Format:
Semi-solid
Formulation:
- Serum-free
- Chemically defined
- Animal component-free
- Protein-free
- DHFR and GS compatible
Ingredients:
- Methylcellulose
- Kolliphor P188 / Pluronic F68
Recommended Applications:
- Selection and cloning of suspension-adapted CHO cells
- Recloning of established, suspension-adapted CHO cells
Advantages:
Enables single-cell cloning in a chemically defined, animal component-free, protein-free medium
ClonaCell™ FLEX
Size:
45 mL
Format:
Semi-solid
Formulation:
- Serum-free
- Chemically defined
- Animal component-free
- Protein-free
- DHFR and GS compatible
Ingredients:
Methylcellulose
Recommended Applications:
- Creating customized semi-solid media for selection and cloning of suspension-adapted CHO cells and hybridomas
- Converting a liquid medium into semi-solid medium for selection and cloning of a wide variety of cell types
- Recloning of established, suspension-adapted CHO cells
Advantages:
- Allows users to create a customized semi-solid medium optimized for a variety of cell types
- Allows users to convert an existing liquid cloning method into a semi-solid cloning method
ClonaCell™-CHO CD Liquid
Size:
500 mL
Format:
Liquid
Formulation:
- Serum-free
- Chemically defined
- Animal component-free
- Protein-free
- DHFR and GS compatible
Ingredients:
Kolliphor P188 / Pluronic F68
Recommended Applications:
- Culture of suspension-adapted CHO cells
- Adaptation of CHO cells for selection and cloning
- Expanding CHO cells following semi-solid cloning
- Limiting dilution cloning of CHO cells when used with ClonaCell™-CHO ACF Supplement
- Cryopreservation of CHO cells when combined with DMSO
Advantages:
- Supports expansion of CHO cells in a chemically defined, animal component-free, protein-free medium
- Compatible with all other ClonaCell™ products
ClonaCell™-CHO ACF Medium
Size:
90 mL
Format:
Semi-solid
Formulation:
- Serum-free
- Animal component-free
- DHFR and GS compatible
Ingredients:
- Methylcellulose
- Supplements
- Kolliphor P188 / Pluronic F68
Recommended Applications:
- Selection and cloning of transfected suspension-adapted CHO cells where serum-free or animal component-free media is required
- Recloning of established, suspension-adapted CHO cells
Advantages:
- Contains only recombinant proteins and synthetic components
- Greater single cell cloning efficiency of CHO cells compared with chemically defined, protein-free media (particularly at low plating densities)
Resources:
ClonaCell™-CHO ACF Supplement
Size:
2.5 mL
Format:
Liquid
Formulation:
- Serum-free
- Animal component-free
- DHFR and GS compatible
Ingredients:
Supplements
Recommended Applications:
- Supplementing chemically defined, protein-free media or semi-solid media to promote growth of CHO cells during single-cell cloning and expansion
- Supporting CHO cell expansion
Advantages:
- Contains only recombinant proteins and chemically defined components at 40X
- Does not contain serum or hydrolysates
ClonaCell™-TCS Medium
Size:
80 mL
Format:
Semi-solid
Formulation:
Serum-containing
Ingredients:
- Methylcellulose
- 2-Mercaptoethanol
- L-Glutamine
Recommended Applications:
- Selection, cloning, and recloning of suspension-adapted or adherent CHO cells and other cell lines
- Applications where high cloning efficiency and robust colony formation is important
Advantages:
Supports high cloning efficiency and robust colony formation for a variety of cell lines such as: CHO-K1, CHO-S, HEK-293, B16F-10, BaF/3, BHK-1, FD-5, Jurkat Daudi, Molt-4, UT-7
Resources:
Collapse Details
Scientific Resources
Protocol
How to Prepare and Plate Semi-Solid Methylcellulose Medium for Cell Culture
Brochure
Increase the Efficiency of Your Hybridoma Workflow with EasySep™ and ClonaCell™
Brochure
ClonaCell™ Media for Hybridoma and Cell Line Development
Tech Tip
Achieving Monoclonality in Hybridoma Cultures
Key Applications
Cell Line Development:
Ling SSM et al. (2015) Instrumental Role of Helicobacter Pylori γ-Glutamyl Transpeptidase in VacA-Dependent Vacuolation in Gastric Epithelial Cells. PLoS One 10(6): e0131460.
Rodríguez L et al. (2015) Generation of Monoclonal Antibodies Specific of The Postfusion Conformation of The Pneumovirinae Fusion (F) Protein. J Virol Methods.
Young J et al. (2015) A Novel Immunoassay to Measure Total Serum Lymphotoxin-α Levels in The Presence of An Anti-LTα Therapeutic Antibody. J Immunol Methods Epub ahead.
Chronopoulou E et al. (2014) Hybridoma Technology for The Generation of Rodent mAbs via Classical Fusion. In: Ossipow V, N Fischer (Eds.) Monoclonal Antibodies: Methods and Protocols, Methods in Molecular Biology. 2nd Ed. New York: Springer Science+Business Media.: pp47–70.
Date Y et al. (2014) Label-Free Impedimetric Immunoassay for Trace Levels of Polychlorinated Biphenyls in Insulating Oil. Anal Chem 86(6): 2989–2996.
García-Barreno B et al. (2014) Characterization of An Enhanced Antigenic Change in The Pandemic 2009 H1N1 Influenza Virus Haemagglutinin. J Gen Virol 95(PART 5): 1033–1042.
Tan GS et al. (2014) Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets The Fusion Domain of Group 2 Influenza A Virus Hemagglutinin. J Virol 88(23): 13580–13592.
Kelly-Cirino CD & Mantis NJ. (2009) Neutralizing Monoclonal Antibodies Directed Against Defined Linear Epitopes on Domain 4 of Anthrax Protective Antigen. Infect Immun 77(11): 4859–4867.
Weidanz J a et al. (2006) Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL Killing. J Immunol 177(8): 5088–5097.
Rodríguez L et al. (2015) Generation of Monoclonal Antibodies Specific of The Postfusion Conformation of The Pneumovirinae Fusion (F) Protein. J Virol Methods.
Young J et al. (2015) A Novel Immunoassay to Measure Total Serum Lymphotoxin-α Levels in The Presence of An Anti-LTα Therapeutic Antibody. J Immunol Methods Epub ahead.
Chronopoulou E et al. (2014) Hybridoma Technology for The Generation of Rodent mAbs via Classical Fusion. In: Ossipow V, N Fischer (Eds.) Monoclonal Antibodies: Methods and Protocols, Methods in Molecular Biology. 2nd Ed. New York: Springer Science+Business Media.: pp47–70.
Date Y et al. (2014) Label-Free Impedimetric Immunoassay for Trace Levels of Polychlorinated Biphenyls in Insulating Oil. Anal Chem 86(6): 2989–2996.
García-Barreno B et al. (2014) Characterization of An Enhanced Antigenic Change in The Pandemic 2009 H1N1 Influenza Virus Haemagglutinin. J Gen Virol 95(PART 5): 1033–1042.
Tan GS et al. (2014) Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets The Fusion Domain of Group 2 Influenza A Virus Hemagglutinin. J Virol 88(23): 13580–13592.
Kelly-Cirino CD & Mantis NJ. (2009) Neutralizing Monoclonal Antibodies Directed Against Defined Linear Epitopes on Domain 4 of Anthrax Protective Antigen. Infect Immun 77(11): 4859–4867.
Weidanz J a et al. (2006) Levels of Specific Peptide-HLA Class I Complex Predicts Tumor Cell Susceptibility to CTL Killing. J Immunol 177(8): 5088–5097.
Hybridoma Development with ClonaCell™ in Different Species:
Chronopoulou E et al. (2014) Hybridoma Technology for the Generation of Rodent mAbs via Classical Fusion. In: Ossipow V, N Fischer (Eds.) Monoclonal Antibodies: Methods and Protocols, Methods in Molecular Biology. 2nd Ed. New York: Springer Science+Business Media.: pp47–70.
Cesaro A et al. (2012) An Inflammation Loop Orchestrated by S100A9 and Calprotectin Is Critical for Development of Arthritis. PLoS One 7(9): e45478.
Smith S a. et al. (2012) Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection. J Virol 86(5): 2665–2675.
Fang L et al. (2008) Essential Role of TNF Receptor Superfamily 25 (TNFRSF25) in the Development of Allergic Lung Inflammation. J Exp Med 205(5): 1037–1048.
Ulbrandt ND et al. (2006) Isolation and Characterization of Monoclonal Antibodies Which Neutralize Human Metapneumovirus In Vitro and In Vivo. J Virol 80(16): 7799–7806.
Grimaldi JC et al. (1999) Depletion of Eosinophils in Mice through the Use of Antibodies Specific for C-C Chemokine Receptor 3 (CCR3). J Leukoc Biol 65(6): 846–853.
Cesaro A et al. (2012) An Inflammation Loop Orchestrated by S100A9 and Calprotectin Is Critical for Development of Arthritis. PLoS One 7(9): e45478.
Smith S a. et al. (2012) Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection. J Virol 86(5): 2665–2675.
Fang L et al. (2008) Essential Role of TNF Receptor Superfamily 25 (TNFRSF25) in the Development of Allergic Lung Inflammation. J Exp Med 205(5): 1037–1048.
Ulbrandt ND et al. (2006) Isolation and Characterization of Monoclonal Antibodies Which Neutralize Human Metapneumovirus In Vitro and In Vivo. J Virol 80(16): 7799–7806.
Grimaldi JC et al. (1999) Depletion of Eosinophils in Mice through the Use of Antibodies Specific for C-C Chemokine Receptor 3 (CCR3). J Leukoc Biol 65(6): 846–853.
Pharmacology and Drug Discovery:
Cabral TM et al. (2014) Development of Neutralizing Monoclonal Antibodies against The Pandemic H1N1 Virus (2009) Using Plasmid DNA Immunogen. J Virol Methods 195: 54–62.
Retamal M et al. (2014) Epitope Mapping of The 2009 Pandemic and the A/Brisbane/59/2007 Seasonal (H1N1) Influenza Virus Haemagglutinins Using mAbs and Escape Mutants. J Gen Virol 95(Pt_11): 2377–2389.
Hostetter DR et al. (2007) Hip Is A Pro-Survival Substrate of Granzyme B. J Biol Chem 282(38): 27865–27874.
Jin C et al. (2006) Immunoglobulin G Specifically Binding Plant N-glycans with High Affinity Could Be Generated in Rabbits But Not in Mice. Glycobiology 16(4): 349–357.
Kuroki M et al. (2005) Preparation of Human IgG and IgM Monoclonal Antibodies for MK-1/Ep-CAM by Using Human Immunoglobulin Gene-Transferred Mouse and Gene Cloning of Their Variable Regions. Anticancer Res 25(6A): 3733–3739.
Retamal M et al. (2014) Epitope Mapping of The 2009 Pandemic and the A/Brisbane/59/2007 Seasonal (H1N1) Influenza Virus Haemagglutinins Using mAbs and Escape Mutants. J Gen Virol 95(Pt_11): 2377–2389.
Hostetter DR et al. (2007) Hip Is A Pro-Survival Substrate of Granzyme B. J Biol Chem 282(38): 27865–27874.
Jin C et al. (2006) Immunoglobulin G Specifically Binding Plant N-glycans with High Affinity Could Be Generated in Rabbits But Not in Mice. Glycobiology 16(4): 349–357.
Kuroki M et al. (2005) Preparation of Human IgG and IgM Monoclonal Antibodies for MK-1/Ep-CAM by Using Human Immunoglobulin Gene-Transferred Mouse and Gene Cloning of Their Variable Regions. Anticancer Res 25(6A): 3733–3739.
Immunology Research:
Flyak AI et al. (2015) Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. Cell 160(5): 893–903.
Fang L et al. (2008) Essential Role of TNF Receptor Superfamily 25 (TNFRSF25) in The Development of Allergic Lung Inflammation. J Exp Med 205(5): 1037–1048.
Matsumoto SC et al. (2006) Retinal Dysfunction in Patients with Chronic Chagas’ Disease Is Associated to Anti-Trypanosoma Cruzi Antibodies That Cross-React with Rhodopsin. FASEB J 21: 1–21.
Fang L et al. (2008) Essential Role of TNF Receptor Superfamily 25 (TNFRSF25) in The Development of Allergic Lung Inflammation. J Exp Med 205(5): 1037–1048.
Matsumoto SC et al. (2006) Retinal Dysfunction in Patients with Chronic Chagas’ Disease Is Associated to Anti-Trypanosoma Cruzi Antibodies That Cross-React with Rhodopsin. FASEB J 21: 1–21.
Cancer Research:
Chen D et al. (2014) Increased Expression of Id1 and Id3 Promotes Tumorigenicity by Enhancing Angiogenesis and Suppressing Apoptosis in Small Cell Lung Cancer. Genes Cancer 5-6(May): 212–225.
Stern HM et al. (2010) Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab. Clin Cancer Res 16(5): 1587–1596.
Chen Y et al. (2007) Armed Antibodies Targeting The Mucin Repeats of The Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models. Cancer Res 67(10): 4924–4932.
Wittman VP et al. (2006) Antibody Targeting to A Class I MHC-Peptide Epitope Promotes Tumor Cell Death. J Immunol 177(6): 4187–4195.
Stern HM et al. (2010) Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab. Clin Cancer Res 16(5): 1587–1596.
Chen Y et al. (2007) Armed Antibodies Targeting The Mucin Repeats of The Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models. Cancer Res 67(10): 4924–4932.
Wittman VP et al. (2006) Antibody Targeting to A Class I MHC-Peptide Epitope Promotes Tumor Cell Death. J Immunol 177(6): 4187–4195.
Contact STEMCELL Technologies
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.
Copyright © 2023 by STEMCELL Technologies. All rights reserved.
